Table 1.
Selected characteristics of the patients of CLL cohort 1 (n = 100)
| CLL cohort 1 |
CLL cohort 2 |
|
|---|---|---|
| Rai-stage at diagnosis, no. of patients | ||
| 0 | 53 | 25 |
| 1 | 26 | 42 |
| 2 | 14 | 13 |
| 3 | 2 | 5 |
| 4 | 5 | 14 |
| Therapy before sample collection | ||
| No, no. of patients | 73 | 79 |
| Time since diagnosis [months], median | 8·7 | 21·1 |
| Median time of follow-up [months] | 47 | NA |
| Yes, no. of patients | 27 | 21 |
| Time since diagnosis [months], median | 95 | 41·4 |
| Time between diagnosis and treatment [months], median |
46 | 11 |
| Steroids only | 3 | 0 |
| Fludarabin, no. of patients | 10 | 10 |
| Fludarabin + cyclophosphamide | 2 | 4 |
| Chlorambucil | 15 | 5 |
| Alemtuzumab | 1 | 2 |
NA, data not available.